[
  {
    "sentence": "It is generally expressed on AML blasts [30–32], but also on normal hematopoietic cells, including the hemopoietic stem cell (HSC) and myeloid progenitors (Figure 1), and on Kupffer cells in the liver [33–35].",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nCAR-cell immunotherapy in hematologic malignancies: challenges and novel approaches.Compared to CD33, the interleukin-3 receptor α chain, CD123, is more frequently expressed on the AML leukemia stem cell (LSC), but it is also present on normal hemopoietic HSC and progenitors (Figure 1) [40], monocytes and some subsets of endothelial cells.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Instead, nearly all HRS cells express CD30 (Figure 1), a tumor necrosis factor receptor, that delivers pro-survival signals through activation of signaling pathways such as PI3-kinase/Akt/mTOR, ERK/MAPK and NF-κB [64].",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "By contrast, B-cell maturation antigen (BCMA), CD19 and CS-1 appear more promising thanks to their reduced off-tumor expression (Figure 1) [72].",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "In AML most of the potential targets are also expressed on healthy hemopoietic progenitors and HSC (Figure 1), thus carrying a potential risk of myelotoxicity that could limit their clinical application.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "For MM, BCMA certainly represents a “CD19-like” antigen, however, BCMA-negative relapses were observed in early BCMA-CART clinical trials [80,95,96](Figure 1) [80].",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Hence, while the quest for identifying the best antigen target continues, a conceptual shift is already taking place seeking to optimize CAR technology using the currently available targets (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Lastly, as shown in Figure 1, a novel interesting approach [105] includes genetic engineering of the normal HSC in order to render them invisible to CART33.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Indeed, CAR T cells recognizing CD123 on TAM within the HL microenvironment as well as in HRS cells effectively killed both TAM and HL cell lines in vitro and displayed potent therapeutic activity against disseminated disease in an in vivo model of HL (Figure 1) [142,143].",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "It is generally expressed on AML blasts [30–32], but also on normal hematopoietic cells, including the hemopoietic stem cell (HSC) and myeloid progenitors (Figure 1), and on Kupffer cells in the liver [33–35].",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nCAR-cell immunotherapy in hematologic malignancies: challenges and novel approaches.Compared to CD33, the interleukin-3 receptor α chain, CD123, is more frequently expressed on the AML leukemia stem cell (LSC), but it is also present on normal hemopoietic HSC and progenitors (Figure 1) [40], monocytes and some subsets of endothelial cells.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Instead, nearly all HRS cells express CD30 (Figure 1), a tumor necrosis factor receptor, that delivers pro-survival signals through activation of signaling pathways such as PI3-kinase/Akt/mTOR, ERK/MAPK and NF-κB [64].",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "By contrast, B-cell maturation antigen (BCMA), CD19 and CS-1 appear more promising thanks to their reduced off-tumor expression (Figure 1) [72].",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "In AML most of the potential targets are also expressed on healthy hemopoietic progenitors and HSC (Figure 1), thus carrying a potential risk of myelotoxicity that could limit their clinical application.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "For MM, BCMA certainly represents a “CD19-like” antigen, however, BCMA-negative relapses were observed in early BCMA-CART clinical trials [80,95,96](Figure 1) [80].",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Hence, while the quest for identifying the best antigen target continues, a conceptual shift is already taking place seeking to optimize CAR technology using the currently available targets (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Lastly, as shown in Figure 1, a novel interesting approach [105] includes genetic engineering of the normal HSC in order to render them invisible to CART33.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Indeed, CAR T cells recognizing CD123 on TAM within the HL microenvironment as well as in HRS cells effectively killed both TAM and HL cell lines in vitro and displayed potent therapeutic activity against disseminated disease in an in vivo model of HL (Figure 1) [142,143].",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "It is generally expressed on AML blasts [30–32], but also on normal hematopoietic cells, including the hemopoietic stem cell (HSC) and myeloid progenitors (Figure 1), and on Kupffer cells in the liver [33–35].",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nCAR-cell immunotherapy in hematologic malignancies: challenges and novel approaches.Compared to CD33, the interleukin-3 receptor α chain, CD123, is more frequently expressed on the AML leukemia stem cell (LSC), but it is also present on normal hemopoietic HSC and progenitors (Figure 1) [40], monocytes and some subsets of endothelial cells.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Instead, nearly all HRS cells express CD30 (Figure 1), a tumor necrosis factor receptor, that delivers pro-survival signals through activation of signaling pathways such as PI3-kinase/Akt/mTOR, ERK/MAPK and NF-κB [64].",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "By contrast, B-cell maturation antigen (BCMA), CD19 and CS-1 appear more promising thanks to their reduced off-tumor expression (Figure 1) [72].",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "In AML most of the potential targets are also expressed on healthy hemopoietic progenitors and HSC (Figure 1), thus carrying a potential risk of myelotoxicity that could limit their clinical application.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "For MM, BCMA certainly represents a “CD19-like” antigen, however, BCMA-negative relapses were observed in early BCMA-CART clinical trials [80,95,96](Figure 1) [80].",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Hence, while the quest for identifying the best antigen target continues, a conceptual shift is already taking place seeking to optimize CAR technology using the currently available targets (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Lastly, as shown in Figure 1, a novel interesting approach [105] includes genetic engineering of the normal HSC in order to render them invisible to CART33.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Indeed, CAR T cells recognizing CD123 on TAM within the HL microenvironment as well as in HRS cells effectively killed both TAM and HL cell lines in vitro and displayed potent therapeutic activity against disseminated disease in an in vivo model of HL (Figure 1) [142,143].",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "It is generally expressed on AML blasts [30–32], but also on normal hematopoietic cells, including the hemopoietic stem cell (HSC) and myeloid progenitors (Figure 1), and on Kupffer cells in the liver [33–35].",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nCAR-cell immunotherapy in hematologic malignancies: challenges and novel approaches.Compared to CD33, the interleukin-3 receptor α chain, CD123, is more frequently expressed on the AML leukemia stem cell (LSC), but it is also present on normal hemopoietic HSC and progenitors (Figure 1) [40], monocytes and some subsets of endothelial cells.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Instead, nearly all HRS cells express CD30 (Figure 1), a tumor necrosis factor receptor, that delivers pro-survival signals through activation of signaling pathways such as PI3-kinase/Akt/mTOR, ERK/MAPK and NF-κB [64].",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "By contrast, B-cell maturation antigen (BCMA), CD19 and CS-1 appear more promising thanks to their reduced off-tumor expression (Figure 1) [72].",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "In AML most of the potential targets are also expressed on healthy hemopoietic progenitors and HSC (Figure 1), thus carrying a potential risk of myelotoxicity that could limit their clinical application.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "For MM, BCMA certainly represents a “CD19-like” antigen, however, BCMA-negative relapses were observed in early BCMA-CART clinical trials [80,95,96](Figure 1) [80].",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Hence, while the quest for identifying the best antigen target continues, a conceptual shift is already taking place seeking to optimize CAR technology using the currently available targets (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Lastly, as shown in Figure 1, a novel interesting approach [105] includes genetic engineering of the normal HSC in order to render them invisible to CART33.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Indeed, CAR T cells recognizing CD123 on TAM within the HL microenvironment as well as in HRS cells effectively killed both TAM and HL cell lines in vitro and displayed potent therapeutic activity against disseminated disease in an in vivo model of HL (Figure 1) [142,143].",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "It is generally expressed on AML blasts [30–32], but also on normal hematopoietic cells, including the hemopoietic stem cell (HSC) and myeloid progenitors (Figure 1), and on Kupffer cells in the liver [33–35].",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nCAR-cell immunotherapy in hematologic malignancies: challenges and novel approaches.Compared to CD33, the interleukin-3 receptor α chain, CD123, is more frequently expressed on the AML leukemia stem cell (LSC), but it is also present on normal hemopoietic HSC and progenitors (Figure 1) [40], monocytes and some subsets of endothelial cells.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Instead, nearly all HRS cells express CD30 (Figure 1), a tumor necrosis factor receptor, that delivers pro-survival signals through activation of signaling pathways such as PI3-kinase/Akt/mTOR, ERK/MAPK and NF-κB [64].",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "By contrast, B-cell maturation antigen (BCMA), CD19 and CS-1 appear more promising thanks to their reduced off-tumor expression (Figure 1) [72].",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "In AML most of the potential targets are also expressed on healthy hemopoietic progenitors and HSC (Figure 1), thus carrying a potential risk of myelotoxicity that could limit their clinical application.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "For MM, BCMA certainly represents a “CD19-like” antigen, however, BCMA-negative relapses were observed in early BCMA-CART clinical trials [80,95,96](Figure 1) [80].",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Hence, while the quest for identifying the best antigen target continues, a conceptual shift is already taking place seeking to optimize CAR technology using the currently available targets (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Lastly, as shown in Figure 1, a novel interesting approach [105] includes genetic engineering of the normal HSC in order to render them invisible to CART33.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Indeed, CAR T cells recognizing CD123 on TAM within the HL microenvironment as well as in HRS cells effectively killed both TAM and HL cell lines in vitro and displayed potent therapeutic activity against disseminated disease in an in vivo model of HL (Figure 1) [142,143].",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "It is generally expressed on AML blasts [30–32], but also on normal hematopoietic cells, including the hemopoietic stem cell (HSC) and myeloid progenitors (Figure 1), and on Kupffer cells in the liver [33–35].",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nCAR-cell immunotherapy in hematologic malignancies: challenges and novel approaches.Compared to CD33, the interleukin-3 receptor α chain, CD123, is more frequently expressed on the AML leukemia stem cell (LSC), but it is also present on normal hemopoietic HSC and progenitors (Figure 1) [40], monocytes and some subsets of endothelial cells.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Instead, nearly all HRS cells express CD30 (Figure 1), a tumor necrosis factor receptor, that delivers pro-survival signals through activation of signaling pathways such as PI3-kinase/Akt/mTOR, ERK/MAPK and NF-κB [64].",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "By contrast, B-cell maturation antigen (BCMA), CD19 and CS-1 appear more promising thanks to their reduced off-tumor expression (Figure 1) [72].",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "In AML most of the potential targets are also expressed on healthy hemopoietic progenitors and HSC (Figure 1), thus carrying a potential risk of myelotoxicity that could limit their clinical application.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "For MM, BCMA certainly represents a “CD19-like” antigen, however, BCMA-negative relapses were observed in early BCMA-CART clinical trials [80,95,96](Figure 1) [80].",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Hence, while the quest for identifying the best antigen target continues, a conceptual shift is already taking place seeking to optimize CAR technology using the currently available targets (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Lastly, as shown in Figure 1, a novel interesting approach [105] includes genetic engineering of the normal HSC in order to render them invisible to CART33.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Indeed, CAR T cells recognizing CD123 on TAM within the HL microenvironment as well as in HRS cells effectively killed both TAM and HL cell lines in vitro and displayed potent therapeutic activity against disseminated disease in an in vivo model of HL (Figure 1) [142,143].",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "It is generally expressed on AML blasts [30–32], but also on normal hematopoietic cells, including the hemopoietic stem cell (HSC) and myeloid progenitors (Figure 1), and on Kupffer cells in the liver [33–35].",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nCAR-cell immunotherapy in hematologic malignancies: challenges and novel approaches.Compared to CD33, the interleukin-3 receptor α chain, CD123, is more frequently expressed on the AML leukemia stem cell (LSC), but it is also present on normal hemopoietic HSC and progenitors (Figure 1) [40], monocytes and some subsets of endothelial cells.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Instead, nearly all HRS cells express CD30 (Figure 1), a tumor necrosis factor receptor, that delivers pro-survival signals through activation of signaling pathways such as PI3-kinase/Akt/mTOR, ERK/MAPK and NF-κB [64].",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "By contrast, B-cell maturation antigen (BCMA), CD19 and CS-1 appear more promising thanks to their reduced off-tumor expression (Figure 1) [72].",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "In AML most of the potential targets are also expressed on healthy hemopoietic progenitors and HSC (Figure 1), thus carrying a potential risk of myelotoxicity that could limit their clinical application.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "For MM, BCMA certainly represents a “CD19-like” antigen, however, BCMA-negative relapses were observed in early BCMA-CART clinical trials [80,95,96](Figure 1) [80].",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Hence, while the quest for identifying the best antigen target continues, a conceptual shift is already taking place seeking to optimize CAR technology using the currently available targets (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Lastly, as shown in Figure 1, a novel interesting approach [105] includes genetic engineering of the normal HSC in order to render them invisible to CART33.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Indeed, CAR T cells recognizing CD123 on TAM within the HL microenvironment as well as in HRS cells effectively killed both TAM and HL cell lines in vitro and displayed potent therapeutic activity against disseminated disease in an in vivo model of HL (Figure 1) [142,143].",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "It is generally expressed on AML blasts [30–32], but also on normal hematopoietic cells, including the hemopoietic stem cell (HSC) and myeloid progenitors (Figure 1), and on Kupffer cells in the liver [33–35].",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nCAR-cell immunotherapy in hematologic malignancies: challenges and novel approaches.Compared to CD33, the interleukin-3 receptor α chain, CD123, is more frequently expressed on the AML leukemia stem cell (LSC), but it is also present on normal hemopoietic HSC and progenitors (Figure 1) [40], monocytes and some subsets of endothelial cells.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Instead, nearly all HRS cells express CD30 (Figure 1), a tumor necrosis factor receptor, that delivers pro-survival signals through activation of signaling pathways such as PI3-kinase/Akt/mTOR, ERK/MAPK and NF-κB [64].",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "By contrast, B-cell maturation antigen (BCMA), CD19 and CS-1 appear more promising thanks to their reduced off-tumor expression (Figure 1) [72].",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "In AML most of the potential targets are also expressed on healthy hemopoietic progenitors and HSC (Figure 1), thus carrying a potential risk of myelotoxicity that could limit their clinical application.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "For MM, BCMA certainly represents a “CD19-like” antigen, however, BCMA-negative relapses were observed in early BCMA-CART clinical trials [80,95,96](Figure 1) [80].",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Hence, while the quest for identifying the best antigen target continues, a conceptual shift is already taking place seeking to optimize CAR technology using the currently available targets (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Lastly, as shown in Figure 1, a novel interesting approach [105] includes genetic engineering of the normal HSC in order to render them invisible to CART33.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Indeed, CAR T cells recognizing CD123 on TAM within the HL microenvironment as well as in HRS cells effectively killed both TAM and HL cell lines in vitro and displayed potent therapeutic activity against disseminated disease in an in vivo model of HL (Figure 1) [142,143].",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "It is generally expressed on AML blasts [30–32], but also on normal hematopoietic cells, including the hemopoietic stem cell (HSC) and myeloid progenitors (Figure 1), and on Kupffer cells in the liver [33–35].",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nCAR-cell immunotherapy in hematologic malignancies: challenges and novel approaches.Compared to CD33, the interleukin-3 receptor α chain, CD123, is more frequently expressed on the AML leukemia stem cell (LSC), but it is also present on normal hemopoietic HSC and progenitors (Figure 1) [40], monocytes and some subsets of endothelial cells.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Instead, nearly all HRS cells express CD30 (Figure 1), a tumor necrosis factor receptor, that delivers pro-survival signals through activation of signaling pathways such as PI3-kinase/Akt/mTOR, ERK/MAPK and NF-κB [64].",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "By contrast, B-cell maturation antigen (BCMA), CD19 and CS-1 appear more promising thanks to their reduced off-tumor expression (Figure 1) [72].",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "It is generally expressed on AML blasts [30–32], but also on normal hematopoietic cells, including the hemopoietic stem cell (HSC) and myeloid progenitors (Figure 1), and on Kupffer cells in the liver [33–35].",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nCAR-cell immunotherapy in hematologic malignancies: challenges and novel approaches.Compared to CD33, the interleukin-3 receptor α chain, CD123, is more frequently expressed on the AML leukemia stem cell (LSC), but it is also present on normal hemopoietic HSC and progenitors (Figure 1) [40], monocytes and some subsets of endothelial cells.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Instead, nearly all HRS cells express CD30 (Figure 1), a tumor necrosis factor receptor, that delivers pro-survival signals through activation of signaling pathways such as PI3-kinase/Akt/mTOR, ERK/MAPK and NF-κB [64].",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "By contrast, B-cell maturation antigen (BCMA), CD19 and CS-1 appear more promising thanks to their reduced off-tumor expression (Figure 1) [72].",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "It is generally expressed on AML blasts [30–32], but also on normal hematopoietic cells, including the hemopoietic stem cell (HSC) and myeloid progenitors (Figure 1), and on Kupffer cells in the liver [33–35].",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nCAR-cell immunotherapy in hematologic malignancies: challenges and novel approaches.Compared to CD33, the interleukin-3 receptor α chain, CD123, is more frequently expressed on the AML leukemia stem cell (LSC), but it is also present on normal hemopoietic HSC and progenitors (Figure 1) [40], monocytes and some subsets of endothelial cells.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "It is generally expressed on AML blasts [30–32], but also on normal hematopoietic cells, including the hemopoietic stem cell (HSC) and myeloid progenitors (Figure 1), and on Kupffer cells in the liver [33–35].",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Compared to CD33, the interleukin-3 receptor α chain, CD123, is more frequently expressed on the AML leukemia stem cell (LSC), but it is also present on normal hemopoietic HSC and progenitors (Figure 1) [40], monocytes and some subsets of endothelial cells.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Instead, nearly all HRS cells express CD30 (Figure 1), a tumor necrosis factor receptor, that delivers pro-survival signals through activation of signaling pathways such as PI3-kinase/Akt/mTOR, ERK/MAPK and NF-κB [64].",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Instead, nearly all HRS cells express CD30 (Figure 1), a tumor necrosis factor receptor, that delivers pro-survival signals through activation of signaling pathways such as PI3-kinase/Akt/mTOR, ERK/MAPK and NF-κB [64].",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "By contrast, B-cell maturation antigen (BCMA), CD19 and CS-1 appear more promising thanks to their reduced off-tumor expression (Figure 1) [72].",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "By contrast, B-cell maturation antigen (BCMA), CD19 and CS-1 appear more promising thanks to their reduced off-tumor expression (Figure 1) [72].",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "In AML most of the potential targets are also expressed on healthy hemopoietic progenitors and HSC (Figure 1), thus carrying a potential risk of myelotoxicity that could limit their clinical application.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "For MM, BCMA certainly represents a “CD19-like” antigen, however, BCMA-negative relapses were observed in early BCMA-CART clinical trials [80,95,96](Figure 1) [80].",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Hence, while the quest for identifying the best antigen target continues, a conceptual shift is already taking place seeking to optimize CAR technology using the currently available targets (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Lastly, as shown in Figure 1, a novel interesting approach [105] includes genetic engineering of the normal HSC in order to render them invisible to CART33.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Indeed, CAR T cells recognizing CD123 on TAM within the HL microenvironment as well as in HRS cells effectively killed both TAM and HL cell lines in vitro and displayed potent therapeutic activity against disseminated disease in an in vivo model of HL (Figure 1) [142,143].",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "In AML most of the potential targets are also expressed on healthy hemopoietic progenitors and HSC (Figure 1), thus carrying a potential risk of myelotoxicity that could limit their clinical application.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "For MM, BCMA certainly represents a “CD19-like” antigen, however, BCMA-negative relapses were observed in early BCMA-CART clinical trials [80,95,96](Figure 1) [80].",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Hence, while the quest for identifying the best antigen target continues, a conceptual shift is already taking place seeking to optimize CAR technology using the currently available targets (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Lastly, as shown in Figure 1, a novel interesting approach [105] includes genetic engineering of the normal HSC in order to render them invisible to CART33.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Lastly, as shown in Figure 1, a novel interesting approach [105] includes genetic engineering of the normal HSC in order to render them invisible to CART33.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Indeed, CAR T cells recognizing CD123 on TAM within the HL microenvironment as well as in HRS cells effectively killed both TAM and HL cell lines in vitro and displayed potent therapeutic activity against disseminated disease in an in vivo model of HL (Figure 1) [142,143].",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Indeed, CAR T cells recognizing CD123 on TAM within the HL microenvironment as well as in HRS cells effectively killed both TAM and HL cell lines in vitro and displayed potent therapeutic activity against disseminated disease in an in vivo model of HL (Figure 1) [142,143].",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  }
]